Beijing, China Jan. 28, 2019, Pharmaron Beijing Co., Ltd. (Pharmaron or the Company; Stock Code: 300759.SZ), announced today its initial public offering (IPO) on the Shenzhen Stock Exchange. Proceeds from the IPO will be used to build the R&D campus/facility at Hangzhou Bay, Ningbo, which further strengthens Pharmaron’s capabilities and capacities to better serve global customers and partners.

Pharmaron, a premier R&D service company, operates globally with over 6,000 employees working at 14 sites and branch offices in China, UK and US. Pharmaron has established diverse drug R&D service capabilities, ranging from lab chemistry, bioscience, safety assessment, CMC and clinical development.

“Thanks to our team for their dedication! Thanks to our partners for the tremendous support! Thanks to the investment community for the great confidence!” said Dr. Boliang Lou, CEO & Chairman, Pharmaron. “We are committed to be a valuable and socially responsible public company. At this new stage, we will move forward with higher standards and be more passionate. With strengthened R&D capabilities, we will better support our partners’ success in discovery, development and commercialization of innovative medicines.”